Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).

Andrzej Jakubowiak, MD, PhD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Sundar Jagannath, MD, David Siegel, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Sagar Lonial, MD, Kevin T. McDonagh, MD, Marcy Vallone, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 1827.

https://doi.org/10.1182/blood.V114.22.1827.1827

Published: 2009

Journal Articles

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.

Suzanne Trudel, MD, Susan Lee, Christopher J. Kirk, PhD, Nashat Gabrail, MD, Sagar Lonial, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Vishal Kukreti, MD, FRCPC, A. Keith Stewart, MD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Francis Buadi, MD, Jeffrey A Zonder, MD, Mark K Bennett, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 1845.

https://doi.org/10.1182/blood.V114.22.1845.1845

Published: 2009

Journal Articles

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., William Bensinger, MD, Melissa Alsina, MD, Nashat Gabrail, MD, Andres Gutierrez, MD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 304.

https://doi.org/10.1182/blood.V114.22.304.304

Published: 2009

Journal Articles

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

David Siegel, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Melissa Alsina, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Nizar J Bahlis, MD, Chaim Shustik, MD, Mai H. Le, MD, Lori Kunkel, MD, Mark K Bennett, PhD, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 303.

https://doi.org/10.1182/blood.V114.22.303.303

Published: 2009

Journal Articles

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

Ravi Vij, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., A. Keith Stewart, MD, Sundar Jagannath, MD, Sagar Lonial, MD, Suzanne Trudel, MD, Andrzej J Jakubowiak, MD, PhD, Andrew Belch, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Mai H. Le, MD, Scott Cruickshank, BA, MS, Mark K Bennett, PhD, Susan Molineaux, PhD, Michael Kauffman, MD, PhD, David Siegel, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 430.

https://doi.org/10.1182/blood.V114.22.430.430

Published: 2009

Journal Articles

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

Luhua Wang, MD, David Siegel, Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Andrzej J Jakubowiak, MD, PhD, Melissa Alsina, MD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Michael Sebag, MD, PhD, Nashat Gabrail, MD, Mai H. Le, MD, Mark K Bennett, PhD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, Robert Z Orlowski, M.D., Ph.D., Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 302.

https://doi.org/10.1182/blood.V114.22.302.302

Published: 2009

Journal Articles

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Sundar Jagannath, MD, Ravi Vij, MD, A. Keith Stewart, MBChB, George Somlo, MD, Andrzej Jakubowiak, MD, PhD, Tony Reiman, MD, Suzanne Trudel, MD, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2008) 112 (11): 864.

https://doi.org/10.1182/blood.V112.11.864.864

Published: 2008

Journal Articles

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Ravi Vij, MD, Michael Wang, MD, Robert Orlowski, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2008) 112 (11): 865.

https://doi.org/10.1182/blood.V112.11.865.865

Published: 2008

NARROW

Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only